Sridhar Nimmagadda, Ph.D.

Headshot of Sridhar Nimmagadda
  • Professor of Radiology and Radiological Science

Research Interests

Molecular imaging probes; chemokine receptors in cancer therapy and imaging; immune modulation therapies; non-invasive assessment of tumor response to therapy. more


Sridhar Nimmagadda, Ph.D. is an Associate Professor of Radiology and Oncology, with joint appointments in Medicine, Clinical Pharmacology, and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine (JHU SOM).  He serves as the Scientific Director of the Johns Hopkins Center for Translational Molecular Imaging, a center dedicated to clinical translation of molecular imaging agents.

Dr. Nimmagadda received a Master of Science degree in Chemistry from the Indian Institute of Technology, Madras and a Ph.D. in Cancer Biology in 2005 from Wayne State University/Karmanos Cancer Institute. Dr. Nimmagadda’s current research is focused on the development of novel imaging agents for chemokine receptors and immune cell related targets (PD-L1), and the application of those agents to quantify drug-target engagement at the tumor. This work is supported by NIH, DOD and several private foundations. He has authored 60 publications that focus on targeted imaging agent development and applying imaging techniques to characterize tumor biology. more


  • Professor of Radiology and Radiological Science
  • Joint Appointment in Medicine
  • Professor of Oncology
  • Professor of Pharmacology and Molecular Sciences

Departments / Divisions

Centers & Institutes



  • B.Sc.; Andhra Loyola College (India) (1994)
  • Ph.D.; Wayne State University School of Medicine (Detroit) (Michigan) (2005)

Additional Training

  • Molecular Imaging, Johns Hopkins University, Baltimore, MD, 2008, Postdoctoral Fellowship

Research & Publications

Research Summary

To understand tumor response to therapy, our laboratory works at the intersection of chemistry and biology, drawing on extensive expertise in chemical, radiochemical, and biocongugate -techniques, molecular imaging methodologies, and animal models. We synthesize imaging agents and therapeutics with a focus on cancer and immune -cell expressed proteins, including chemokine receptors (e.g., CXCR4) and the immune checkpoint proteins (e.g., PD-L1), and integrate those novel chemical tools with innovative imaging techniques to guide and optimize molecularly targeted combination therapies.

Technology Expertise Keywords

Imaging; PET; SPECT; Radiopharmaceutical; Immunotherapy; Chemokine receptors

Selected Publications

View all on PubMed

Nimmagadda S, Pullambhatla M, Green G, Bhujwalla ZM, Pomper, MG., Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100-PET. Cancer Res, 70, 3935-3944, 2010.

De Silva RA, Peyre KP, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S.,  Imaging CXCR4 expression in human cancer xenografts: Evaluation of monocyclam [64Cu]AMD3465. J Nucl Med., 2011 Jun;52(6):986-93.

Chatterjee S, Lesniak W, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Behnam Azad B, Poper MG, Nimmagadda S.  A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget, 2016 Mar 1;7(9):10215-27

Lesniak W, Oskolkov N, Yang X, Pomper MG, Nimmagadda S*, McMahon MT*. Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI Nanoplatform. Nano Lett, 2016 Apr 13;16(4):2248-53.

Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7. PMID:30457978

Contact for Research Inquiries

Email me

Academic Affiliations & Courses

Graduate Program Affiliation

Pharmacology and Molecular Sciences

Activities & Honors


  • AACR
Is this you? Edit Profile
back to top button